Cipher Pharmaceuticals Inc

TSX:CPHCanadaView on OTCQX International

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

Contact Information

Headquarters

5750 Explorer Drive,, Suite 404MISSISSAUGA, ON, Canada L4W 0A9

Phone

905-602-5840

Fax

---

Executives

Chairman of the Board, Interim Chief Executive Officer

Craig Mull

Chief Financial Officer, Company Secretary

Bryan Jacobs

Vice President of Sales and Marketing

Lorne Markowitz

Vice President - Regulatory Affairs

Louise Blythe

Vice President - Medical and Clinical Affairs

Lynne Bulger